{"id":885273,"date":"2026-06-22T16:58:15","date_gmt":"2026-06-22T16:58:15","guid":{"rendered":"https:\/\/www.europesays.com\/us\/885273\/"},"modified":"2026-06-22T16:58:15","modified_gmt":"2026-06-22T16:58:15","slug":"blood-pressure-medication-recalled-nationwide-over-failed-dissolution-practices-fda","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/885273\/","title":{"rendered":"Blood pressure medication recalled nationwide over failed dissolution practices: FDA"},"content":{"rendered":"<\/p>\n<p>(<a href=\"https:\/\/www.newsnationnow.com\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">NewsNation<\/a>) \u2014 An Indian company is <a href=\"https:\/\/www.newsnationnow.com\/us-news\/recalls\/\" data-type=\"link\" data-id=\"https:\/\/www.newsnationnow.com\/us-news\/recalls\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">voluntarily recalling<\/a> more than 11,000 bottles of blood pressure medication because of failed dissolution testing.<\/p>\n<p>The recall applies to 100 and 1,000 tablet bottles of Chlorthalidone sold nationwide because they \u201cfailed dissolution specifications,\u201d according to the <a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/ires\/?Event=99136\" data-type=\"link\" data-id=\"https:\/\/www.accessdata.fda.gov\/scripts\/ires\/?Event=99136\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Food and Drug Administration<\/a>.<\/p>\n<p>Dissolution testing evaluates how well a drug dissolves and releases its active ingredients when placed in liquid, according to <a href=\"https:\/\/www.pion-inc.com\/blog\/what-is-in-vitro-dissolution-testing\" data-type=\"link\" data-id=\"https:\/\/www.pion-inc.com\/blog\/what-is-in-vitro-dissolution-testing\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">pharmaceutical technology company Pion<\/a>. This helps to \u201cassess the performance and quality of different drug formulations, as well as to ensure consistency in drug release between different batches.\u201d<\/p>\n<p>\t<a href=\"https:\/\/www.newsnationnow.com\/business\/waymo-recalls-robotaxis-construction-incidents\/?ipid=promo-link-block1\" class=\"promo-link__link\" target=\"&quot;_blank&quot;\" rel=\"nofollow noopener\"><br \/>\n\t\tWaymo recalls thousands of robotaxis after construction zone incidents\t<\/a><\/p>\n<p>Chlorthalidone, a diuretic medication, is used to treat high blood pressure and can also reduce swelling related to heart, kidney, or liver disease, according to the <a href=\"https:\/\/my.clevelandclinic.org\/health\/drugs\/20711-chlorthalidone-tablets\" data-type=\"link\" data-id=\"https:\/\/my.clevelandclinic.org\/health\/drugs\/20711-chlorthalidone-tablets\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Cleveland Clinic<\/a>. <\/p>\n<p>The pills were manufactured by Inventia Healthcare Limited of India and distributed by Rising Pharma Holdings, Inc. of East Brunswick, New Jersey. <\/p>\n","protected":false},"excerpt":{"rendered":"(NewsNation) \u2014 An Indian company is voluntarily recalling more than 11,000 bottles of blood pressure medication because of&hellip;\n","protected":false},"author":3,"featured_media":885274,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[3601,210,1060,67,132,68],"class_list":["post-885273","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-author","tag-health","tag-medication","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116794825638492033","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/885273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=885273"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/885273\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/885274"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=885273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=885273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=885273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}